Motilal Oswal Remains Positive on UTI AMC; Goldman Sachs Downgrades Dr. Reddy's Laboratories
Buy, Sell or Hold: Motilal Oswal maintains buy on UTI AMC; Goldman Sachs downgrades Dr Reddy’s Laboratories
The Economic TimesImage: The Economic Times
Motilal Oswal has maintained a 'buy' rating on UTI Asset Management Company (AMC) and Aditya Birla Sun Life AMC, highlighting positive trends in assets under management (AUM) and strong systematic investment plan (SIP) inflows. Conversely, Goldman Sachs has downgraded its outlook on Dr. Reddy's Laboratories due to evolving growth dynamics in the pharmaceutical sector.
- 01Motilal Oswal maintains a 'buy' rating on UTI AMC and Aditya Birla Sun Life AMC.
- 02The firm cites steady AUM trends and strong SIP inflows as positive indicators.
- 03Goldman Sachs has downgraded Dr. Reddy's Laboratories.
- 04The downgrade reflects a cautious stance on certain pharmaceutical companies.
- 05Market dynamics are shifting, affecting growth projections.
Advertisement
In-Article Ad
Brokerages are adopting a selective approach in the asset management sector while expressing caution towards certain pharmaceutical companies. Motilal Oswal has reaffirmed its 'buy' rating on UTI Asset Management Company (AMC) and Aditya Birla Sun Life AMC, attributing this to consistent trends in assets under management (AUM) and robust inflows from systematic investment plans (SIPs). These factors suggest improving long-term growth potential despite some short-term margin pressures. On the other hand, Goldman Sachs has taken a more conservative stance on Dr. Reddy's Laboratories, indicating a downgrade due to changing growth dynamics within the pharmaceutical industry. This mixed outlook reflects the evolving landscape of these sectors, with asset management showing resilience while pharmaceuticals face challenges.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
Do you think asset management companies will continue to perform well in the current market?
Connecting to poll...
More about Motilal Oswal
Infosys Shares Drop Over 3% Following Q4 Results Amid Mixed Analyst Reactions
The Economic Times • Apr 24, 2026
Fujiyama Power Systems Shares Surge Following 'Buy' Rating from Motilal Oswal
The Economic Times • Apr 23, 2026
HCL Tech Shares Plunge as Brokers Downgrade Targets Amid Weak Q4 Results
The Economic Times • Apr 22, 2026
Read the original article
Visit the source for the complete story.
